Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine- differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1882-1890

  Borre, Michael ^a   Nerstrøm, Benni ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TUMOR CELL; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; CHROMOGRANINS; ENDOTHELIAL GROWTH FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON WILLEBRAND FACTOR;

EID: 0034069026     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
2. Weidner, N., Carroll P. R., Flax, J., Blumenfeld, W., and Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 143: 401-409, 1993.
3. Brawer, M. K., Deering, R. E., Brown, M. T., Preston, S. D., and Bigler, S. A. Predictors of pathologic stage in prostatic carcinoma. Cancer (Phila.), 3: 678-687, 1994.
4. Silberman, M. A., Partin, A. W., Veltri, R. W., and Epstein, J. I. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathological stage in Gleason sum 5-7 adenocarcinoma of the prostate. Cancer (Phila.), 79: 772-779, 1997.
5. Lissbrant, I. F., Stattin, P., Damber, J. E., and Bergh, A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate, 33: 38-45, 1997.
6. Offersen, B. V., Borre, M., and Overgaard, J. Immunohisto-chemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. APMIS, 106: 463-469, 1998.
7. Borre, M., Offersen, B. V., Nerstrøm, B., and Overgaard, J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br. J. Cancer, 78: 940-944, 1998.
8. Folkman, J., and Klagsburn, M. Angiogenic factors. Science (Washington DC), 235: 442-447, 1987.
9. Montesano, R., Vassalli, J. D., Baird, A., Guillemin, R., and Orci, L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. USA, 83: 7297-7301, 1986.
10. Ishikawa, F., Miyazono, K., Hellman, U., Drexler, H., Wemstedt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W., and Heldin, C. H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial growth factor. Nature (Lond.), 338: 557-562, 1989.
11. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
12. Claffey, K. P., and Robinson, G. S. Regulation of VEGF/VPF expression in tumor-cells - consequences for tumor-growth and metastasis. Cancer Metastasis Rev., 15: 165-176, 1996.
13. Ferrara, N., and Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 161: 851-858, 1989.
14. Keck. P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., and Connolly, D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (Washington DC), 246: 1309-1312, 1989.
15. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989.
16. Connolly, D. T., Heuvelman, D. M., Nelson, R., Olander, J. V., Eppley, B. L., Delfino, J. J., Siegel, N. R., Leimgruber, R. M., and Feder, J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Investig., 84: 1470-1478, 1989.
17. 2-terminal amino acid sequence of a guinea pig tumor-secreted vascular permeability factor. Cancer Res., 50: 1774-1778, 1990.
18. Schweioki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
19. Frank, S., Hubner, G., Breier, G., Longaker, M. T., Greenhalgh, D. G., and Werner, S. Regulation of VEGF expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem., 270: 12607-12613, 1995.
20. Kieser, A., Weich, H., Brandner, G., Marme, D., and Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
21. Terman, B. I., Dougher, V. M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Commun., 787: 1579-1586, 1992.
22. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Washington DC), 255: 989-991, 1992.
23. Harper, M. E., Glynne-Jones, E., Goddard, L., Thurston, V. J., and Griffiths, K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br. J. Cancer, 74: 910-916, 1996.
24. Jackson, M. W., Bentel, J. M., and Tilley, W. D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol., 157: 2323-2328, 1997.
25. Ferrer, F. A., Miller, L. J., Andrawis, R. I., Kurtzman, S. H., Albertsen, P. C., Laudone, V. P., and Kreutzer, D. L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol., 157: 2329-2333, 1997.
26. Di Sant'Agnese, P. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer (Phila.), 70: 254-268, 1992.
27. Borre, M., Nerstrøm, B., and Overgaard, J. The natural history of prostate cancer based on a Danish population treated with no intent to cure. Cancer (Phila.), 80: 917-928, 1997.
28. Hermanek, P., and Sobin, L. H. UICC TNM Classification of Malignant Tumors. Berlin: Springer-Verlag, 1992.
29. Mostofi, F. K., Sesterhenn, I. A., and Sobin, L. H. Histological Typing of Prostate Tumors. Geneva: World Health Organization, 1980.
30. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
31. Deftos, L. J., Nakada, S., Burton, D. W., Di Sant'Agnese, P., Cockett, A. T. K., and Abrahamsson, P. A. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology, 48: 58-62, 1996.
32. Weinstein, M. H., Partin, A. W., Veltri, R. W., and Epstein, J. I. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum. Pathol., 27: 683-687, 1996.
33. Krijnen, J. L. M., Bogdanowicz, J. F. A. T., Seldenrijk, C. A., Mulder, P. G. H., and van der Kwast, T. H. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J. Urol., 158: 171-174, 1997.
34. Bonkhoff, H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate, 8: 18-22, 1998.
35. Abrahamsson, P. A., Wadstrom, L. B., Alumets, J., Falkmer, S., and Grimelius, L. Peptide hormone- and serotinin-immunoreactive tumour cells in carcinoma of the prostate. Pathol. Res. Pract., 182: 298-307, 1987.
36. Byar, D. P., and Mostofi, F. K. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Cancer (Phila.), 30: 5-13, 1972.
37. Siegal, J. A., Yu, E., and Brawer, M. K. Topography of neovascularity in human prostate carcinoma. Cancer (Phila.), 75: 2545-2551, 1995.